Adjuvant therapy for pancreatic cancer

Recent Results in Cancer Research

Volumn 196, Issue , 2012, Pages 65-88

  Sultana, Asma ^a   Cox, Trevor ^a   Ghaneh, Paula ^a   Neoptolemos, John P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MITOMYCIN C; MITOXANTRONE;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; EVIDENCE BASED MEDICINE; HUMAN; INTRAOPERATIVE RADIOTHERAPY; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84870027019     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-31629-6_5     Document Type: Article

References (84)

1. Abrams R, Lillemoe K, Piantadosi S (2001) Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 358:1565
2. Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, Konski AA, Benson AB, Macdonald JS, Rich TA, Willett CG (2012) Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 82 (2): 809-816. doi:10.1016/j.ijrobp.2010.11.039
3. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, Maisonneuve P, Sebastiano PD (2011) Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. doi:10.1245/s10434-011-2110-8
4. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150 (3): 466-473. doi: 10.1016/j.surg.2011.07.006
5. Bakkevold K, Arnesjo B, Dahl O, Kambestad B (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater-results of a controlled, prospective, randomised multicentre study. Eur J Can 29A (5): 698-703
6. Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ 3rd (2011) Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol 18 (4): 1122-1129. doi: 10.1245/s10434-010-1401-9
7. Bassi C, Stocken DD, Olah A, et al. (2005) The influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Digestive Surgery in press
8. Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB 3rd, MacDonald J, Willett CG (2008) Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26 (36): 5918-5922. doi:10.1200/JCO.2008.18.6288
9. Berlin J, Catalano PJ, Feng Y, Lowy AM, Blackstock AW, Philip PA, McWilliams RR, Abbruzzese JL, Benson AB (2010) ECOG 2204: an intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC). J Clin Oncol 28[15 (May supplement)]:abstract 4034
10. Boeck S, Ankerst DP, Heinemann V (2007) The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and metaanalysis. Oncology 72 (5-6): 314-321. doi:10.1159/000113054
11. Brunner TB, Grabenbauer GG, Meyer T, Golcher H, Sauer R, Hohenberger W (2007) Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the interdisciplinary working group gastrointestinal tumours (AIO, ARO, and CAO). BMC Cancer 7:41. doi:10.1186/1471-2407-7-41
12. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Buchler MW, Neoptolemos JP, Pancreatic Cancer Meta- Analysis G (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 143 (1): 75-83, discussion 83. doi 10.1001/archsurg.2007.17
13. Chua YJ, Cunningham D (2005) Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol 23 (20): 4532-4537
14. Coquard R, Ayzac L, Gilly F et al (1997) Intraoperative radiotherapy in resected pancreatic cancer: feasibility and results. Radiother Oncol 44: 271-275
15. Costello E, Neoptolemos JP (2011) Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroenterol Hepatol 8 (2): 71-73. doi:10.1038/nrgastro.2010.214
16. Cunningham D, Chau I, Stocken D et al (2009) Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27 (33): 5513-5518
17. Diener MK, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Knaebel H, Büchler MW (2011) Pylorus-preserving pancreaticoduodenectomy (ppWhipple) versus pancreaticoduodenectomy (classicWhipple) for surgical treatment of periampullary and pancreatic carcinoma. In: Cochrane database of systematic reviewsed
18. Doughlass H (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006-2010
19. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 (21): 3496-3502. doi:10.1200/JCO.2007.15.8634
20. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136 (1): 187-195. doi:10.1053/j.gastro. 2008.09.067
21. Fossati V, Cattaneo G, Zerbi A et al (1995) The role of intraoperative therapy by electron beam and combination of adjuvant chemotherapy and external radiotherapy in carcinoma of the pancreas. Tumori 81 (1): 23-31
22. Garofalo M, Flannery T, Regine W (2006) The case for adjuvant chemoradiation for pancreatic cancer. Best Pract Res Clin Gastroenterol 20 (2): 403-416
23. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS medicine 7 (4):e1000267. doi:10.1371/journal.pmed.1000267
24. Hardacre JM, Mulcahy MF, Small Jr. W, Talamonti M, Obel JC, Rocha Lima CS, Safran H, Lenz H, Chiorean EG, Link CJ (2011) Effect of the addition of algenpantucel-L immunotherapy to standard adjuvant therapy on survival in patients with resected pancreas cancer. J Clin Oncol 29 (supplement 4):abstract 236
25. Hayashibe A, Kameyama M, Shinbo M, Makimoto S (2007) Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer. Ann Surg Oncol 14 (1): 190-194. doi:10.1245/s10434-006-9110-0
26. Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, Clavien PA (2008a) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248 (6): 1014-1022. doi:10.1097/SLA. 0b013e318190a6da
27. Heinrich S, Pestalozzi BC, Schafer M, Weber A, Bauerfeind P, Knuth A, Clavien PA (2008b) Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 (15): 2526-2531. doi: 10.1200/JCO.2007.15.5556
28. Hiraoka T, Uchino R, Kanemitsu K et al (1990) Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol 7 (1-3): 201-207
29. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10 (4): 511-518. doi:10.1016/j.gassur.2005.09.016
30. Jamieson NB, Carter CR, McKay CJ, Oien KA (2011) Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 17 (10): 3316-3331. doi:10.1158/1078-0432.CCR-10- 3284
31. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60 (5): 277-300. doi: 10.3322/caac.20073
32. Kalser M, Ellenberg S (1985) Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120: 899-903
33. Klinkenbijl J, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (6): 776-784
34. Knaebel HP, Marten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal H, Fritz S, Herrmann T, Goldschmidt H, Mansmann U, Debus J, Diehl V, Buchler MW (2005) Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: study protocol [ISRCTN62866759]. BMC Cancer 5 (1):37
35. Koshy M, Landry J, Cavanaugh S et al (2005) A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 61 (4): 965-966
36. Kosuge T, Kiuchi T, Mukai K, Kakizoe T (2006) A multicenter randomised controlled trial to evaluate the effect of adjuvant cisplatin and 5-Fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 36 (3): 159-165
37. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101 (7): 587-592. doi: 10.1002/jso.21527
38. Le Scodan R, Mornex F, Girard N, Mercier C, Valette PJ, Ychou M, Bibeau F, Roy P, Scoazec JY, Partensky C (2009) Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFROFFCD9704 trial and literature review.Ann Oncol 20 (8): 1387-1396. doi:10.1093/annonc/mdp015
39. Li D, Moughan J, Crane CH, Hoffman JP, Regine W, Abrams RA, Safran H, Freedman GM, Guha C, Abbruzzese JL (2011) Association of RecQ1 A159C polymorphism with overall survival of patients with resected pancreatic cancer: a replication study in RTOG 9704. J Clin Oncol 29 (supplement 4):abstract 156
40. Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malyapa RS, Hull M, Trinkaus K, Tan BR Jr (2008) Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg 248 (2): 145-151. doi:10.1097/SLA.0b013e318181e4e9
41. Maeda A, Boku N, Fukutomi A, Kondo S, Kinoshita T, Nagino M, Uesaka K (2008) Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan adjuvant study group of pancreatic cancer (JASPAC-01). Jpn J Clin Oncol 38 (3): 227-229. doi:10.1093/jjco/hym178
42. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Deviere J, Van Laethem JL (2009) Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15 (8): 2913-2919. doi:10.1158/1078-0432.CCR-08- 2080
43. Marten A, Schmidt J, Ose J, Harig S, Abel U, Munter MW, Jager D, Friess H, Mayerle J, Adler G, Seufferlein T, Gress T, Schmid R, Buchler MW (2009) A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2. BMC Cancer 9:160. doi:10.1186/1471-2407-9-160
44. Marten A, Schmidt J, Debus J, Harig S, Lindel K, Klein J, Bartsch D, Capussotti L, Zülke C, Buchler M (2010) CapRI: final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon- 2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). J Clin Oncol 28[18 (June 20 Supplement)]:LBA4012
45. Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, Friess H (2007) Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 94 (3): 265-273. doi:10.1002/bjs.5716
46. Michiels S, Piedbois P, Burdett S et al (2005) Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21 (1): 119-125
47. Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, Hop WC, Kazemier G, van Eijck CH (2008) Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 248 (6): 1031-1041. doi:10.1097/SLA.0b013e318190c53e
48. Morak MJ, Pek CJ, Kompanje EJ, Hop WC, Kazemier G, van Eijck CH (2010) Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled study. Cancer 116 (4): 830-836. doi:10.1002/cncr.24809
49. Neoptolemos J, Dunn J, Stocken D et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358 (9293): 1576-1585
50. Neoptolemos J, Stocken D, Freiss H et al (2004) A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210
51. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) European study group for Pancreatic C. Adjuvant chemotherapy withfluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304 (10): 1073-1081. doi 10.1001/jama.2010. 1275
52. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J, Oettle H (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 26 (15S):LBA4504, (May 20 Supplement)
53. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer. A randomised controlled trial. JAMA 297 (3): 267-277
54. Office for National Statistics (2010) Cancer statistics registration: registration of cancers diagnosed in 2008, England
55. Office for National Statistics (2010) Mortality statistics: deaths registered in England and wales 2008
56. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR (2007) A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14 (7): 2088-2096. doi:10.1245/s10434-007-9384-x
57. Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA (2012) What the mouse has told us about human pancreatic cancer. Gastroenterology in press
58. Picozzi V, Kozarek R, Traverso L (2003) Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185: 476-480
59. Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW (2011) American college of surgeons oncology gmulticenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 22 (2): 348-354. doi:10.1093/annonc/mdq384
60. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299 (9): 1019-1026. doi:10.1001/jama.299.9.1019
61. Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG (2011) Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18 (5): 1319-1326. doi:10.1245/s10434-011-1630-6
62. Reni M (2010) Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol 16 (39): 4883-4887
63. Reni M, Panucci M, Ferreri A et al (2001) Effect of local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 50 (3): 651-658
64. Rizzato C, Campa D, Giese N, Werner J, Rachakonda PS, Kumar R, Schanne M, Greenhalf W, Costello E, Khaw KT, Key TJ, Siddiq A, Lorenzo-Bermejo J, Burwinkel B, Neoptolemos JP, Buchler MW, Hoheisel JD, Bauer A, Canzian F (2011) Pancreatic cancer susceptibility loci and their role in survival. PLoS ONE 6 (11):e27921. doi:10.1371/journal.pone.0027921
65. Shore S, Raraty M, Ghaneh P, Neoptolemos J (2003) Chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 18 (11-12): 1049-1069
66. Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG (2011) The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 81 (5): 1328-1335. doi:10.1016j.ijrobp.2010.07.1993
67. Sindelar W, Kinsella T (1986) Randomised trial of intraoperative radiotherapy in resected carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 12 (suppl. 1):148
68. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J (2007) Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 246 (5): 734-740. doi:10.1097/SLA.0b013e318156eef3
69. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104 (9): 1440-1451. doi:10.1038/bjc.2011.110
70. Sperti C, Pasquali C, Piccoli A et al (1997) Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21: 195-200
71. Stathis A, Moore M (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172
72. Stocken D, Buchler M, Dervenis C, et al. (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer, pp 1-10
73. Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J, Ghaneh P (2007) Metaanalyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25 (18): 2607-2615
74. Takada T, Amano H, Yasuda H et al (2002) Is postoperative adjuvant chemotherapy useful for gall bladder carcinoma? A phase III multicentre prospective randomised controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (8): 1685-1695
75. Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomised phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed-dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (18): 3383-3384
76. Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR, Viret F (2010) Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol 36 (10): 987-992. doi:10.1016/j.ejso.2010.07.003
77. Tuveson D, Hanahan D (2011) Translational medicine: cancer lessons from mice to humans. Nature 471 (7338): 316-317. doi:10.1038/471316a
78. Tuveson DA, Neoptolemos JP (2012) Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148: 1-4. doi:10.1016/j.cell. 2011.12.021
79. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K (2009)A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer 101 (6): 908-915. doi 10.1038/sj.bjc.6605256
80. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M, Collette L, Budach V, Lutz M, Van Cutsem E, Haustermans K (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28 (29): 4450-4456. doi:10.1200/JCO.2010.30.3446
81. Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T, Uhl W, Van Tienhoven G, Bachet JB, Marechal R, Hendlisz A, Bali M, Demetter P, Ulrich F, Aust D, Luttges J, Peeters M, Mauer M, Roth A, Neoptolemos JP, Lutz M (2011) New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol. doi:10.1093/annonc/mdr351
82. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 (21): 3487-3495. doi:10.1200/JCO.2007.15.8642
83. Yoshitomi H, Togawa A, Kimura F, Ito H, Shimizu H, Yoshidome H, Otsuka M, Kato A, Nozawa S, Furukawa K, Miyazaki M, Pancreatic Cancer Chemotherapy Program of the Chiba University Department of General Surgery Affiliated Hospital G (2008) A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 113 (9): 2448-2456. doi 10.1002/cncr.23863
84. Zerbi A, Fossati V, Parolini D (1994) Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 73: 2930-2935